Clinical trials: Platelet Inhibition
Immune Mediated Anemia, Immune Mediated Thrombocytopenia
Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias
Background: People who have a blood stem cell transplant can sometimes develop cytopenia. This means that their levels of one or more types of blood cell, such as the red cells or platelets, are lower than they should be.
- Conditions
- Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD
- Trial name
- NCT05509582
- Testing
- fostamatinib
- Where
- United States
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Coronary Syndrome
Tirofiban and Enoxaparin in High Risk Coronary Intervention
Patients undergoing coronary angioplasty are frequently treated with new drugs that stop blood platelets working and so improve the success of the procedure. Individual patients may vary in the dose of the drug required.
- Trial name
- NCT00790387
- Testing
- Enoxaparin, Tirofiban, unfractionated heparin
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- The Prince Charles Hospital
Thrombosis
The Association Between Platelet Inhibition and Perioperative Major Adverse Cardiac Events In Post-Percutaneous Coronary Intervention (PCI) Patients Undergoing Non-Cardiac Surgery
This prospective, multicentre, observational study aims to test pre-operative platelet function when taking anti-platelet medications.
- Trial name
- NCT01707459
- Where
- Canada
- Volunteers
- 201 people
- Sponsor
- University Health Network, Toronto
Bleeding
Platelet Inhibition and Bleeding in Patients Undergoing Emergent Cardiac Surgery
The aim of the study is to evaluate if there is an association between platelet inhibition and surgery-related bleeding in patients undergoing emergent cardiac surgery during dual antiplatelet therapy.
- Trial name
- NCT01468597
- Where
- Austria
- Volunteers
- 167 people
- Sponsor
- Medical University of Graz
Acute Chest Syndrome
Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin
The study evaluates the effect of platelet inhibition and / or lipid lowering in non-ACS-patients with symptoms suggestive for ACS, and elevated high-sensitivity troponin values
- Trial name
- GRAY-ZONE (NCT03820466)
- Testing
- Aspirin, Atorvastatin
- Where
- 7 sites in Germany
- Volunteers
- 68 people
- Sponsor
- Dr. med. Mahir Karakas
Platelet Aggregation
A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540
This study is designed to provide data on platelet aggregation of PA32540 plus clopidogrel dosed separately compared to EC aspirin 81 mg plus EC omeprazole 40 mg plus clopidogrel dosed concomitantly.
- Trial name
- NCT01557335
- Testing
- Plavix® and PA32540, EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- POZEN
Coronary Artery Disease, Drug Resistance
Efficacy of Adjusted Clopidogrel Dose in Patients With Insufficient Platelet Inhibition
This study is a prospective, single-center evaluation of the efficacy of clopidogrel dose adjustment in patients with insufficient platelet inhibition after elective coronary stent implantation.
- Trial name
- NCT00302913
- Testing
- Adjustment of clopidogrel dose
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- University Heart Center Freiburg - Bad Krozingen
Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition
The purpose of this study is to assess the the 1-year rates of ischemic and bleeding complications in patients whose dual antiplatelet therapy regimen post-PCI has been determined with the use of a clinical algorithm that…
- Conditions
- Percutaneous Coronary Intervention, Dual Antiplatelet Therapy, Aspirin, Clopidogrel
- Trial name
- TRIAGE (NCT01582217)
- Where
- United States
- Volunteers
- 318 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Platelet Reactivity
Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
This is a single-center, randomized, single-blind, investigator-initiated, pharmacodynamic study with a parallel design. Patients with ST elevation myocardial infarction, undergoing primary percutaneous coronary intervention will…
- Trial name
- NCT01463163
- Testing
- Prasugrel, Ticagrelor
- Where
- Greece
- Volunteers
- 50 people
- Sponsor
- University of Patras
Hypercholesterolemia, Thrombosis
The Inhibition of Platelet Antiaggregating Activity of Clopidogrel by Atorvastatin Detected by Erythromycin Breath Test: a Metabolic Inhibition of Hepatic Cytochrome P450-3A
The objective of this study is to determine if the action of the drug called clopidogrel, that you will start taking, will be decreased by another drug called atorvastatin, that you will also start taking.
- Trial name
- NCT00004564
- Testing
- Clopidogrel, Atorvastatin
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
Coronary Artery Disease
Duration of Platelet Inhibition by Aspirin
The well established importance of regular aspirin administration stands on firm grounds, as large meta-analyses have shown this therapy to significantly reduce the risk of death.
- Trial name
- NCT00671021
- Testing
- Platelet aggregation
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Pancreatic Cancer Resectable
Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head
This randomized, controlled clinical trial compares the perioperative treatment with acetylsalicylic acid (aspirin) in patients with cancer of the pancreatic head.
- Trial name
- ASAP (NCT05637567)
- Testing
- Acetylsalicylic acid
- Volunteers
- 170 people
- Sponsor
- German Cancer Research Center
Ehlers-Danlos Syndrome Hypermobility Type (hEDS), Ehlers-Danlos Syndrome (EDS)
Regenerative Medicine for Joint Hypermobility and Instability
This clinical trial is designed to evaluate whether a stepwise injection-based treatment approach can reduce pain and improve function in adults with joint hypermobility, connective tissue laxity, and joint instability.
- Conditions
- Ehlers-Danlos Syndrome Hypermobility Type (hEDS), Ehlers-Danlos Syndrome (EDS), Joint Hypermobility, Joint Instability
- Trial name
- NCT07688096
- Testing
- Dextrose 20% Prolotherapy, Autologous Platelet-Rich Plasma, Doxycycline Hyclate Injectable (Investigational)
- Volunteers
- 100 people
- Sponsor
- Manhattan Pain Medicine, PLLC
Thrombosis, Arterial Occlusive Diseases
Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization
The goal of this clinical trial is to learn if a blood clotting test called thromboelastography with platelet mapping (TEG-PM) can guide blood-thinning medication decisions in adults more than 60 years and older with peripheral…
- Conditions
- Thrombosis, Arterial Occlusive Diseases, Thromboelastography (TEG), Peripheral Arterial Disease(PAD)
- Trial name
- TARGET (NCT07597239)
- Testing
- Aspirin, Clopidogrel, Ticagrelor
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Massachusetts General Hospital
Coronary Artery Stenosis, Maximal Platelet Aggregation
Comparison of Platelet Inhibition With Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel According to Hepatic Cytochrome 2C19 Allele (CYP2C19) Polymorphism
The purpose of this study was to determine the impact of adjunctive cilostazol on platelet inhibition in carriers and non-carriers of the loss-of-function CYP2C19 allele.
- Conditions
- Coronary Artery Stenosis, Maximal Platelet Aggregation, Late Platelet Aggregation, High Post-Treatment Platelet Reactivity
- Trial name
- ACCEL2C19 (NCT00891670)
- Testing
- cilostazol, clopidogrel, aspirin
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Gyeongsang National University Hospital
Peripheral Arterial Disease
The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease
The purpose of this study is to understand how the drug rivaroxaban improves symptoms associated with peripheral artery disease.
- Trial name
- NCT05009862
- Testing
- Rivaroxaban 2.5 Mg Oral Tablet, Aspirin 81Mg Ec Tab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Vanderbilt University Medical Center
Acute Coronary Syndrome, STEMI
Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS
Elderly individuals are increasingly represented among patients with acute coronary syndrome (ACS). Dual antiplatelet therapy (DAPT) with aspirin and an oral P2Y12 receptor inhibitor has an established role in the prevention of…
- Conditions
- Acute Coronary Syndrome, STEMI, NSTEMI, Coronary Artery Disease
- Trial name
- PlinytheElder (NCT04739384)
- Testing
- Ticagrelor 90mg, Ticagrelor 60 mg
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Federico II University
ST-Segment Elevation Myocardial Infarction
Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction
To compare efficacy and safety of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
- Trial name
- NCT02075125
- Testing
- Prasugrel 60 mg, Ticagrelor 180 mg
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- Dong-A University
Congenital Heart Defects, Blood Platelet Disorders
Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)
PICOLO is a double blind placebo controlled phase II dose ranging, dose escalating study in patients of Blalock-Taussig age categories (neonates and infants/toddlers), to determine the dose providing inhibition of platelet…
- Trial name
- NCT00115375
- Testing
- Clopidogrel (SR25990)
- Where
- 6 sites in United States, Belgium and 4 more
- Volunteers
- 92 people
- Sponsor
- Sanofi
Platelet Aggregation Inhibitors, Anti-inflammatory Agent
ACCEL-LOADING-ACS Study
The purpose of this study is to determine whether adjunctive cilostazol loading/maintenance to standard treatment (aspirin, clopidogrel, and statin) is effective in reduction of major adverse cardiovascular events, platelet…
- Conditions
- Platelet Aggregation Inhibitors, Anti-inflammatory Agent, Myocardial Reperfusion Injury
- Trial name
- NCT01354808
- Testing
- Dual Anti-Platelet Therapy (DAPT), Triple Anti-Platelet Therapy (TAPT)
- Where
- South Korea
- Volunteers
- 220 people
- Sponsor
- Gyeongsang National University Hospital